Proactive Investors - Run By Investors For Investors

GW Pharmaceutical to raise US$104mln in US

GW Pharmaceutical to raise US$104mln in US

Cannabis based medicine firm GW Pharmaceutical (LON:GWP) confirmed it will raise US$104mln through the listing of American depository shares (ADS) onto the NASDAQ.

The company, which has developed a cannabinoid treatment for spasticity caused by multiple sclerosis, has already launched one product and is developing a pipeline of other medicines.

Just yesterday, the company revealed results, which it called promising, from a study in which its new product Epidiolex was given to children and young adults with a form of hard to treat epilepsy.

Epidiolex takes the form of a flavoured syrup. It does not contain THC, the psychoactive compound in marijuana.

GW chief executive Justin Glover said: "We have been delighted with the continued support from US investors.

“Today's successful financing follows the recent release of promising data on our pipeline product Epidiolex in treating children and young adults with treatment-resistant epilepsy, and allows us not only to advance rapidly the development of this product candidate but also to commence preparations for future commercialisation.”

"We are very excited about GW's future prospects, not only for Epidiolex but also for the rest of our product portfolio, and look forward to reporting continued progress during the remainder of this year and beyond."

Through the underwritten funding, 1.7mln ADS are being sold at a price of US$86.83 each. GW itself is issuing 1.2mln of the ADS, whilst separately a further 500,000 ADS will be sold on behalf of certain existing shareholders which include the company’s directors.

The funding is expected to close on June 25.

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
DNA sequence
The cell therapy specialist also reported there had been industry interest around its main programmes
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use